Depatux-M and temozolomide in advanced high-grade glioma

Sophie Hirsch1,2,3,4, Cristiana Roggia5, Saskia Biskup6, Benjamin Bender7, Irina Gepfner-Tuma1,2,3, Franziska Eckert3,8, Daniel Zips3,8, Nisar P Malek4,9, Helmut Wilhelm10, Mirjam Renovanz11, Ghazaleh Tabatabai1,2,3.
  1. Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  2. Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany.
  3. Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  4. Center for Personalized Medicine, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  5. Department of Genetics, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  6. CeGaT and Praxis for Human Genetics, Tübingen, Germany.
  7. Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  8. Department of Radiation Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  9. Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  10. Department of Ophtalmology, Division of Neuro-ophtalmology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  11. Department of Neurosurgery, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.